Literature DB >> 22926603

Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study.

Jimmi Nielsen1, Rene Ernst Nielsen, Christoph U Correll.   

Abstract

We aimed to identify factors associated with greater clozapine response to guide targeted clozapine use. The study was based on data from the Danish Psychiatric Central Research Register and the National Prescription Database including schizophrenia patients initiating clozapine from 1997 to 2006. Cox regression was used to identify predictors of time to psychiatric hospitalization and all-cause discontinuation from first clozapine prescription. In a 2-year mirror-image design, multiple logistic regression models were used to identify predictors of psychiatric hospitalization. Among 633 schizophrenia patients starting clozapine, shorter time to admission was predicted by increasing number of different antipsychotics (hazard ratio [HR], 1.08/trial; confidence interval [CI], 1.01-1.15/trial) and admissions (HR, 1.04/admission; CI, 1.03-1.05/admission) before first clozapine prescription, earlier onset of schizophrenia (HR, 0.98/y; CI, 0.96-0.99/y), and lower clozapine dose (HR, 0.07/100 mg; CI, 0.03-0.13/100 mg). In the 2-year mirror-image model, during clozapine treatment, there was a significant reduction in bed-days (269.9 days [CI, 238.3-287.8 days] to 64.2 days [CI, 53.0-79.3 days], P < 0.001) and admissions (3.4 [CI, 3.1-3.6] to 2.2 [CI, 1.9-2.5], P < 0.011). Being admitted during clozapine treatment was also associated with more antipsychotic trials (odds ratio [OR], 1.11; CI, 1.00-1.22) and admissions before clozapine initiation (OR, 1.08; CI, 1.04-1.11) and female sex (OR, 1.84; CI, 1.31-2.58). Although the study design does not allow any causal inferences, all 3 models suggested a lower number of psychiatric hospitalizations and antipsychotic trials before clozapine initiation to be associated with greater clozapine response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926603     DOI: 10.1097/JCP.0b013e318267b3cd

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

2.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

3.  Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?

Authors:  Vincenzo Prisco; Teresa Iannaccone; Umberto Volpe; Michele Fabrazzo
Journal:  BMJ Case Rep       Date:  2015-06-01

Review 4.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

Review 5.  The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.

Authors:  Christoffer Polcwiartek; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-12-02       Impact factor: 4.530

Review 6.  Genetics of Schizophrenia: Ready to Translate?

Authors:  Claire Foley; Aiden Corvin; Shigeki Nakagome
Journal:  Curr Psychiatry Rep       Date:  2017-09       Impact factor: 5.285

7.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

Review 8.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

9.  A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Authors:  Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith
Journal:  Community Ment Health J       Date:  2021-05-29

10.  Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients.

Authors:  J Frank; M Lang; S H Witt; J Strohmaier; D Rujescu; S Cichon; F Degenhardt; M M Nöthen; D A Collier; S Ripke; D Naber; M Rietschel
Journal:  Mol Psychiatry       Date:  2014-06-03       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.